Combining radiation with oxaliplatin: A review of experimental results

Cancer/Radiotherapie

Volumn 12, Issue 1, 2008, Pages 61-67

  Hermann, R M ^a   Rave Frank M ^a   Pradier, O ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b CHU MORVAN   (France)

Author keywords

In vitro; Oxaliplatin; Radiotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PROTEIN P53; RADIOSENSITIZING AGENT;

APOPTOSIS; CANCER RADIOTHERAPY; CELL CYCLE; CELL SURVIVAL; CELL VIABILITY; DNA REPAIR; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SINGLE DRUG DOSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CISPLATIN; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39949085050     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2007.12.006     Document Type: Review

References (51)

1. Bartelink H., Kallman R.F., Rapacchietta D., and Hart G.A. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation. Radiother Oncol 6 (1986) 61-74
2. Begg A.C. Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 19 (1990) 1183-1189
3. Benzina S., Debomy F., Bergerat J.P., Denis J.M., Gueulette J., Dufour P., et al. The cytotoxicity of high-linear energy transfer radiation is reinforced by oxaliplatin in human glioblastoma. Cancer Lett 254 (2007) 54-62
4. Benzina S., Fischer B., Miternique-Grosse A., Dufour P., Denis J.M., Bergerat J.P., et al. Cell death induced in a human glioblastoma cell line by p(65)+Be neutrons combined with cisplatin. Life Sci 79 (2006) 513-518
5. Bleiberg H., and de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25 (1998) 32-39
6. Brown J.M., and Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5 (2005) 231-237
7. Calugaru V., Taillibert S., Lang P., Simon J.M., Delattre J.Y., and Mazeron J.J. Chimiothérapie néoadjuvante suivie d'une radiothérapie adaptée à la réponse tumorale dans les tumeurs germinales séminomateuses du système nerveux central: expérience de l'hôpital de la Pitié-Salpêtrière et revue de la littérature. Cancer Radiother 11 (2007) 122-128
8. Caney C., Singh G., Lukka H., and Rainbow A.J. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin. Int J Radiat Biol 80 (2004) 291-299
9. Chater S., Amara S., Moussata D., Bozec A., Omezzine A., Romestaing P., et al. Differential effects of ionizing radiation and platinum-derivative chemotherapy on apoptotic pathways in testicular germ cells. Int J Radiat Biol 83 (2007) 269-278
10. Cividalli A., Ceciarelli F., Livdi E., Altavista P., Cruciani G., Marchetti P., et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 52 (2002) 1092-1098
11. Deutsch E., Kaliski A., Maggiorella L., and Bourhis J. Les stratégies nouvelles pour moduler les effets de l'irradiation: exemples d'interactions entre biomodulateurs et radiothérapiestar, open [New strategies to interfere with radiation response: "biomodulation" of radiation therapy]. Cancer Radiother 9 (2005) 69-76
12. Dewit L. Combined treatment of radiation and cis-diamminedichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13 (1987) 403-426
13. Durdux C. Sels de platine et radiothérapie : vingt ans de pratique. Cancer Radiother 8 Suppl 1 (2004) S88-S94
14. Espinosa M., Martinez M., Aguilar J.L., Mota A., De la Garza J.G., Maldonado V., et al. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemother Pharmacol 55 (2005) 301-305
15. Faivre S., Chan D., Salinas R., Woynarowska B., and Woynarowski J.M. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66 (2003) 225-237
16. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56 (1996) 4881-4886
17. Folkvord S, Flatmark K, Seierstad T, Hansen Ree A. In vitro and in vivo radiosensitization of colorectal carcinoma cells by oxaliplatin in combination with 5-fluoruracil. Proceedings of the 10th international Wolfsberg Meeting on Molecular Radiation Biology/Oncology. Vol 7, 2007. Editors: Baumann M, Bodis S, Dikomey E, van der Kogel A, Overgaard J, Rodemann HP. ISBN 3-9808819-4-6.
18. Frankenberg-Schwager M., Kirchermeier D., Greif G., Baer K., Becker M., and Frankenberg D. Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae. Toxicology 212 (2005) 175-184
19. Fujie Y., Yamamoto H., Ngan C.Y., Takagi A., Hayashi T., Suzuki R., et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 35 (2005) 453-463
20. Gorodetsky R., Levy-Agababa F., Mou X., and Vexler A.M. Combination of cisplatin and radiation in cell culture: effect of duration of exposure to drug and timing of irradiation. Int J Cancer 75 (1998) 635-642
21. Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Fresco L., Collingwood M., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet 358 (2001) 781-786
22. Greene M.H. Is cisplatin a human carcinogen. J Nat Cancer Inst 84 (1992) 306-312
23. Hector S., Bolanowska-Higdon W., Zdanowicz J., Hitt S., and Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48 (2001) 398-406
24. Hennequin C., and Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 38 (2002) 223-230
25. Joubert A., and Foray N. Radiosensibilité intrinsèque et cassures double-brin de l'ADN dans les cellules humaines. Cancer Radiother 11 (2007) 129-142
26. Kartalou M., and Essigmann J.M. Mechanisms of resistance to cisplatin. Mut Res 478 (2001) 23-43
27. Kjellstrom J., Kjellen E., and Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncologica 44 (2005) 687-693
28. Koivusalo R., Krausz E., Ruotsalainen P., Helenius H., and Hietanen S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 62 (2002) 7364-7371
29. Krause M., Zips D., Thames H.D., Kummermehr J., and Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol 80 (2006) 112-122
30. Leblanc J.M., and Raaphorst P. Evaluation of cisplatin treatment given concurrently with pulsed irradiation in cisplatin sensitive and resistant human ovarian carcinoma cell lines. Int J Radiat Biol 81 (2005) 429-435
31. Lebwohl D., and Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34 (1998) 1522-1534
32. Magné N., Fischel J.L., Formento P., Etienne M.C., Dubreuil A., Marcié S., et al. Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology 64 (2003) 280-287
33. Martelli L., Di Mario F., Botti P., Ragazzi E., Martelli M., and Kelland L. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status. Biochem Pharmacol 74 (2007) 20-27
34. Mathé G., Kidani Y., Noji M., Maral R., Bourut C., and Chenu E. Antitumor activity of 1-OHP in mice. Cancer Lett 27 (1985) 135-143
35. Moretti L., Roelandts M., Berghmans T., and Van Houtte P. Les traitements adjuvants dans les cancers bronchiques non à petites cellules. Cancer Radiother 11 (2007) 53-58
36. Nakamoto S., Mitsuhashi N., Takahashi T., Sakurai H., and Niibe H. An interaction of cisplatin and radiation in two-rat yolk sac tumour cell lines with different radiosensitivities in vitro. Int J Radiat Biol 70 (1999) 747-753
37. Nehme A., Baskaran R., Nebel S., Fink D., Howell S.B., Wang J.Y., et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 79 (1999) 1104-1110
38. Ohe Y. Chemoradiotherapy for lung cancer. Expert Opin Pharmacother 6 (2005) 2793-2804
39. Pendyala L., Kidani Y., Perez R., Wilkes J., Bernacki R.J., and Creaven P.J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97 (1995) 177-184
40. Rabik C.A., and Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33 (2007) 9-23
41. Rakitina T.V., Vasilevskaya I.A., and O'Dwyer P.J. Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines. Biochem Pharmacol 73 (2007) 1715-1726
42. Rave-Fränk M., Schmidberger H., Christiansen H., Boll C., Lehmann J., and Weiss E. Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells. Int J Radiat Biol 83 (2007) 41-47
43. Reardon J.T., Vaisman A., Chaney S.G., and Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59 (1999) 3968-3971
44. Rodel C., Liersch T., Hermann R.M., Arnold D., Reese T., Hipp M., et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25 (2007) 110-117
45. Sanderson B.J.S., Ferguson L.R., and Denny W.A. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mut Res 355 (1996) 59-70
46. Schmidt W., and Chaney S.G. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53 (1993) 799-805
47. Stordal B., Pavlakis N., and Davey R. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev 33 (2007) 347-357
48. Toscano F., Parmentier B., Fajoui Z.E., Estornes Y., Chayvialle J.A., and Saurin J.C. Abello J. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells. Biochem Pharmacol 74 (2007) 392-406
49. Turchi J.J., Henkels K.M., and Zhou Y. Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK. Nucleic Acids Res 28 (2000) 4634-4641
50. Wilson G.D., Bentzen S.M., and Harari P.M. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16 (2006) 2-9
51. Zamble D.B., Mu D., Reardon J.T., Sancar A., and Lippard S.J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35 (1996) 10004-10013